secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001213900-24-013294
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q1 revenue jumps to $978k; OneRF Ablation System receives FDA clearance
--------------------------------------------------------------------------------

- Product revenue $978k in Q1 fiscal 2024, up from $115k in Q1 2023.
- Net loss $3.3M vs $1.7M YoY; cash $2.7M at Dec 31, 2023.
- FDA 510(k) clearance for OneRF Ablation System in Dec 2023; limited commercial launch expected Q2 2024.
- Zimmer Biomet sales force trained for Evo sEEG; new accounts expected to drive revenue growth.
- Raised $2.8M via ATM offering at avg $1.45/share in Dec 2023 – Jan 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390024013294/0001213900-24-013294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390024013294/ea193484-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-013294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer